Vizient Clinical Data Base Offers Insights into CAR-T and Bone Marrow Transplants at 2019 Transplantation & Cellular Therapy Meeting of ASBMT and CIBMTR

IRVING, Texas–(BUSINESS WIRE)–Vizient announces that it will present research insights on CAR-T
therapy and bone marrow transplants, based on data from its Clinical
Database/Resource Manager (CDB/RM™) as part of the 2019
Transplantation & Cellular Therapy Meeting of ASBMT and CIBMTR

to be held Feb. 20-24 in Houston.

Vizient will present four posters at the event which is focused on
recent progress in basic science, translational research and clinical
studies in all areas of blood and marrow transplantation and cellular
therapy. The Vizient posters are:

  • Emerging Trends in Chimeric Antigen Receptor T-Cell Immunotherapy
    in Adults from the Vizient CDB/RM.
    The poster covers a
    retrospective cohort of 735 patients 18 years and older undergoing
    CAR-T procedures between October 2017 and August 2018. It describes
    trends in adult patient populations, outcomes, and adverse events
    using the CAR-T procedure codes in administrative data. Research and
    presentation by Alyssa Hartsell Harris, lead analyst at Vizient.
  • Emerging Trends in Chimeric Antigen Receptor T-Cell Immunotherapy
    in Young Adults and Pediatric Patients from the Vizient CDB/RM
    The poster covers a retrospective cohort of 40 patients under 25 years
    undergoing CAR-T procedures between October 2017 and August 2018 and
    describes trends in young adult patient populations, outcomes and
    hospitals using the CAR-T procedure codes. Research and presentation
    by Alyssa Hartsell Harris.
  • Resource Utilization in Allogeneic Bone Marrow Harvest Procedures:
    A Multi-Hospital Perspective
    . The poster examines the top drivers
    of cost for more than 5,500 bone marrow extraction encounters in the
    inpatient and outpatient setting in 2017 using the Vizient CDB/RM.
    Research by Gwen Ledford, presentation by Sam Hohmann, research
    analytics director at Vizient.
  • Variation in Scope of Practice of Advanced Practice Providers
    (APPs) Involved in Care of BMT/HCST Patients.
    The poster is a
    retrospective cohort study of 63,447 BMT/HSCT encounters at hospitals
    participating in Vizient’s CDB/RM between Q4 2014 and Q3 2018. The
    analysis includes a review of advanced practice provider roles,
    patient demographics, and encounter characteristics. Research and
    presentation by Sam Hohmann.

“What is unique about the research posters on CAR-T therapies is the
freshness of the source data for patient outcomes. This therapy only
received ICD-10 codes in October 2017 and CMS data is not yet available.
The Vizient CDB has collected 12 months of patient data and we have used
that as a base for both posters on this topic,” said Gladys J. Epting,
Ph.D., associate vice president, analytics, at Vizient. Additionally,
the posters on bone marrow transplants offer new insights into cost
drivers for extraction encounters and of care management provided by
advanced practice providers.

About Vizient, Inc.

Vizient, Inc., the largest member-driven health care performance
improvement company in the country, provides innovative data-driven
solutions, expertise and collaborative opportunities that lead to
improved patient outcomes and lower costs. Vizient’s diverse membership
base includes academic medical centers, pediatric facilities, community
hospitals, integrated health delivery networks and non-acute health care
providers and represents approximately $100 billion in annual purchasing
volume. The Vizient brand identity represents the integration of VHA
Inc., University HealthSystem Consortium and Novation, which combined in
2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM)
segment, including Sg2, which was acquired in 2016. In 2018, Vizient
again received a World’s Most Ethical Company designation from the
Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with
locations in Chicago and other cities across the United States. Please
visit as
well as our newsroomblogTwitterLinkedIn and YouTube pages
for more information about the company.


Angie Boliver
(972) 830-7961

error: Content is protected !!